公开(公告)号：US20220185877A1

公开(公告)日：2022-06-16

申请号：US17570954

申请日：2022-01-07

Applicant: Bristol-Myers Squibb Company

Inventor： Brenda L. Stevens ,  Mark W. Rixon ,  Scott R. Presnell

IPC: C07K16/24 ,  C07K16/46

Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.

公开(公告)号：US10358489B2

公开(公告)日：2019-07-23

申请号：US15620358

申请日：2017-06-12

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Brenda L. Stevens ,  Mark W. Rixon ,  Scott R. Presnell

IPC: A61K39/395 ,  C07K16/24 ,  C07K16/46 ,  A61K39/00

Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.

公开(公告)号：US09783606B2

公开(公告)日：2017-10-10

申请号：US14576278

申请日：2014-12-19

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Brenda L. Stevens ,  Alison Witte ,  Mark W. Rixon ,  Josephine M. Cardarelli ,  Thomas D. Kempe ,  Scott R. Presnell ,  Mohan Srinivasan ,  Susan C. Wong ,  Guodong Chen ,  Hui Wei ,  Stanley R. Krystek ,  Lumelle A. Schneeweis ,  Paul O. Sheppard ,  Indrani Chakraborty

IPC: C12N15/09 ,  C07K16/24 ,  C07K16/46 ,  A61K39/00

CPC classification number: C07K16/244 ,  A61K2039/505 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.

公开(公告)号：US20130315911A1

公开(公告)日：2013-11-28

申请号：US13898544

申请日：2013-05-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Brenda L. Stevens ,  Alison Witte ,  Mark W. Rixon ,  Josephine M. Cardarelli ,  Thomas D. Kempe ,  Scott R. Presnell ,  Mohan Srinivasan ,  Susan C. Wong ,  Guodong Chen ,  Hui Wei ,  Stanley R. Krystek ,  Lumelle A. Schneeweis ,  Paul O. Sheppard ,  Indrani Chakraborty

IPC: C07K16/46

CPC classification number: C07K16/244 ,  A61K2039/505 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.